BA
ABBV icon

Bridgewater Associates’s AbbVie ABBV Stock Holding History

Bridgewater Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.6M Buy
30,362
+16,153
+114% +$3.58M 0.03% 349
2025
Q4 		$3.25M Sell
14,209
-246,480
-95% -$56.1M 0.01% 652
2025
Q3 		$60.4M Sell
260,689
-337,603
-56% -$68.7M 0.24% 76
2025
Q2 		$111M Buy
598,292
+493,340
+470% +$91.7M 0.45% 51
2025
Q1 		$22M Sell
104,952
-181,411
-63% -$35.3M 0.1% 168
2024
Q4 		$50.9M Buy
286,363
+81,791
+40% +$15M 0.23% 81
2024
Q3 		$40.4M Sell
204,572
-83,953
-29% -$15.7M 0.23% 81
2024
Q2 		$49.5M Sell
288,525
-161,254
-36% -$26.7M 0.26% 64
2024
Q1 		$81.9M Sell
449,779
-157,114
-26% -$27.1M 0.41% 47
2023
Q4 		$94.1M Buy
606,893
+30,933
+5% +$4.51M 0.53% 41
2023
Q3 		$85.9M Sell
575,960
-58,345
-9% -$8.57M 0.52% 39
2023
Q2 		$85.5M Buy
634,305
+222,875
+54% +$32.7M 0.53% 40
2023
Q1 		$65.6M Buy
411,430
+381,328
+1,267% +$58.3M 0.4% 54
2022
Q4 		$4.86M Sell
30,102
-182,648
-86% -$28M 0.03% 366
2022
Q3 		$28.6M Buy
212,750
+130,900
+160% +$18.8M 0.14% 125
2022
Q2 		$12.5M Buy
81,850
+6,334
+8% +$968K 0.05% 287
2022
Q1 		$12.2M Buy
75,516
+33,661
+80% +$4.89M 0.05% 253
2021
Q4 		$5.67M Sell
41,855
-33,241
-44% -$3.93M 0.03% 269
2021
Q3 		$8.1M Buy
75,096
+22,491
+43% +$2.57M 0.04% 223
2021
Q2 		$5.92M Buy
+52,605
New +$5.92M 0.04% 303
2021
Q1 		– Sell
-25,294
Closed -$2.71M – 458
2020
Q4 		$2.71M Buy
+25,294
New +$2.43M 0.02% 265

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bridgewater Associates's ABBV Position: Q1 2026 in Review

Bridgewater Associates increased its AbbVie (ABBV) stake by 114% in Q1 2026, buying an estimated $3.58M and bringing the position to 30,362 shares worth $6.6M. The position accounts for 0.03% of the portfolio, ranked #349.

Bridgewater Associates first reported a position in ABBV in Q4 2020 and has held it in 21 quarters since. The position peaked at $111M in Q2 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Bridgewater Associates held 30,362 shares of AbbVie worth $6.6M as of Q1 2026.
  • Bridgewater Associates bought 16,153 AbbVie shares in Q1 2026, an estimated $3.58M.
  • AbbVie made up 0.03% of Bridgewater Associates's portfolio in Q1 2026, its #349 holding.
  • Bridgewater Associates first reported a position in AbbVie in Q4 2020 and has held it in 21 quarters since.
  • Bridgewater Associates's AbbVie position peaked at $111M in Q2 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.